Avalo Therapeutics (AVTX) Q4 2024 Annual Earnings
AVTX·Reported April 4, 2025·Before market open
Avalo Therapeutics reported Q4 2024 revenue of $192.0K (-66.4% YoY). Diluted EPS came in at $-7.95 (-32.9% YoY), missed the $0.58 consensus by $8.53.
Revenue
$192.0K
Diluted EPS
$-7.95missed by $8.53
Consensus: $0.58
Financial Snapshot
Trailing eight quarters through Q4 2024
Q4 2024 Earnings FAQ
Common questions about Avalo Therapeutics's Q4 2024 earnings report.
Avalo Therapeutics (AVTX) reported Q4 2024 earnings on April 4, 2025 before market open.
Avalo Therapeutics reported revenue of $192.0K and diluted EPS of $-7.95 for Q4 2024.
EPS missed the consensus estimate of $0.58 by $8.53.
Compared to the same quarter a year prior, revenue declined 66.4% from $571.0K a year earlier and diluted EPS declined 32.9% from $-5.98.
You can read the 10-K periodic report (0001628280-25-013986) directly on SEC EDGAR. The filing index links above go to sec.gov.